| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-14-2024 | 06-30-2024 | 10-Q | |
| 2 | 05-13-2024 | 03-31-2024 | 10-Q | |
| 3 | 03-22-2024 | 12-31-2023 | 10-K | |
| 4 | 11-10-2023 | 09-30-2023 | 10-Q | |
| 5 | 09-01-2023 | 06-30-2023 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
B of A Securities analyst Geoff Meacham maintains Turnstone Biologics (NASDAQ:TSBX) with a Buy and lowers the price target f...
Piper Sandler analyst Joseph Catanzaro maintains Turnstone Biologics (NASDAQ:TSBX) with a Overweight and lowers the price ta...
Turnstone Biologics stock drops after Phase 1 STARLING trial data reveals mixed results for TIDAL-01 in metastatic colorectal c...
Turnstone Biologics (NASDAQ:TSBX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of...
Overall response rate ("ORR") of 25% and 50% disease control rate ("DCR") observed in first four evaluable pati...
